CN112592386A - Red light mediated nucleic acid anchoring type fluorescent probe and preparation method and application thereof - Google Patents
Red light mediated nucleic acid anchoring type fluorescent probe and preparation method and application thereof Download PDFInfo
- Publication number
- CN112592386A CN112592386A CN202011263517.1A CN202011263517A CN112592386A CN 112592386 A CN112592386 A CN 112592386A CN 202011263517 A CN202011263517 A CN 202011263517A CN 112592386 A CN112592386 A CN 112592386A
- Authority
- CN
- China
- Prior art keywords
- compound
- probe
- nucleic acid
- red light
- fluorescent probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004873 anchoring Methods 0.000 title claims abstract description 44
- 230000001404 mediated effect Effects 0.000 title claims abstract description 30
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 27
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 20
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 20
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 68
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- 238000003384 imaging method Methods 0.000 claims abstract description 20
- 239000000523 sample Substances 0.000 claims description 71
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 44
- 229940126214 compound 3 Drugs 0.000 claims description 23
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 22
- 229940125904 compound 1 Drugs 0.000 claims description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- NTXPGLDNLXNMFN-QFIPXVFZSA-N CC(C)(C)OC(=O)N([C@@H](CCCCN)C(=O)O)C(=O)OCC1=C2CC3=CC=CC=C3C2=CC=C1 Chemical compound CC(C)(C)OC(=O)N([C@@H](CCCCN)C(=O)O)C(=O)OCC1=C2CC3=CC=CC=C3C2=CC=C1 NTXPGLDNLXNMFN-QFIPXVFZSA-N 0.000 claims description 13
- 229940125782 compound 2 Drugs 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- 235000019260 propionic acid Nutrition 0.000 claims description 11
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 11
- 230000014759 maintenance of location Effects 0.000 claims description 10
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 8
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 7
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 238000010511 deprotection reaction Methods 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 3
- 230000005760 tumorsuppression Effects 0.000 claims description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 12
- 210000001519 tissue Anatomy 0.000 abstract description 11
- 238000004132 cross linking Methods 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 230000006907 apoptotic process Effects 0.000 abstract description 7
- 210000000805 cytoplasm Anatomy 0.000 abstract description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract description 3
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 24
- 239000003068 molecular probe Substances 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 210000003462 vein Anatomy 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 230000002601 intratumoral effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 238000005286 illumination Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000011002 quantification Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008045 co-localization Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- ROGODJHHEBREAB-UHFFFAOYSA-N (2Z)-2-[(2E,4E,6E)-7-[1-[6-(2,5-dioxopyrrolidin-1-yl)oxy-6-oxohexyl]-3,3-dimethyl-5-sulfoindol-1-ium-2-yl]hepta-2,4,6-trienylidene]-1-ethyl-3,3-dimethylindole-5-sulfonate Chemical compound CC1(C)C2=CC(S([O-])(=O)=O)=CC=C2N(CC)\C1=C/C=C/C=C/C=C/C(C(C1=CC(=CC=C11)S(O)(=O)=O)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CCC1=O ROGODJHHEBREAB-UHFFFAOYSA-N 0.000 description 2
- JYEVQYFWINBXJU-QFIPXVFZSA-N (2s)-6-(9h-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 JYEVQYFWINBXJU-QFIPXVFZSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 108091092330 cytoplasmic RNA Proteins 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000012984 biological imaging Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000000584 ultraviolet--visible--near infrared spectrum Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1074—Heterocyclic compounds characterised by ligands containing more than three nitrogen atoms as heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/14—Macromolecular compounds
- C09K2211/1441—Heterocyclic
- C09K2211/145—Heterocyclic containing oxygen as the only heteroatom
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Radiology & Medical Imaging (AREA)
- Materials Engineering (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a red light mediated nucleic acid anchoring type fluorescent probe and a preparation method and application thereof, wherein the fluorescent probe has the capability of carrying out cross-linking reaction with RNA in cytoplasm under the mediation of singlet oxygen, and realizes the imaging of a tumor tissue in a long window period; meanwhile, the phenomenon of serious apoptosis of tumor cells is found after the RNA is crosslinked, and the diagnosis and treatment of the tumor are integrated.
Description
Technical Field
The invention belongs to the technical field of small molecule fluorescent probe biological imaging and tumor treatment, and particularly relates to a novel anchoring type molecular probe, a preparation method thereof and application of the probe in multi-modal imaging and tumor treatment.
Background
It is known that cancer is one of the most major diseases threatening human life and health, and it is a great obstacle to the healthy development of the economic society. According to data released by the national cancer center, the incidence rate of tumors in China increases year by year, and the trend of the tumors is younger, so that the development of materials and new technologies for tumor diagnosis and treatment is urgent. In recent years, researchers have designed various materials for tumor imaging and therapy, however, the materials often cannot be enriched in tumor tissues for a long time, thereby greatly reducing the bioavailability of the materials. Therefore, the development of a novel probe aiming at overcoming the high metabolism of tumor tissues has obvious clinical significance. Biological cross-linking reaction means that a compound can chemically react with macromolecules in an organism to form covalent bonds under the stimulation of certain exogenous conditions.
Disclosure of Invention
In order to overcome the problems of the existing materials and the prior art, the invention constructs a novel anchoring molecular probe, and long-time living body fluorescence, photoacoustic imaging and tumor treatment are carried out by utilizing the advantages of the anchoring molecular probe, such as crosslinking capability group, better biocompatibility, active targeting integrin and near infrared emission.
The invention adopts the following technical scheme:
a novel red light mediated nucleic acid anchoring type fluorescent probe has the following chemical structural formula:
the preparation method of the red light mediated nucleic acid anchoring type fluorescent probe comprises the following steps:
(1) carrying out deprotection on tert-butyloxycarbonyl-fluorenylmethyloxycarbonyl-lysine, and then reacting with 3- (2-furan) propionic acid to obtain a compound 1;
(2) activating carboxyl by the compound 1, reacting with cyclopeptide cRGD to obtain a compound 2, and deprotecting to obtain a compound 3;
(3) and reacting the compound 3 with Cy7 SE to obtain the red light mediated nucleic acid anchoring type fluorescent probe.
The preparation method of the red light mediated nucleic acid anchoring type fluorescent probe specifically comprises the following steps:
(1) reacting tert-butyloxycarbonyl-fluorenylmethoxycarbonyl-lysine with 3- (2-furan) propionic acid after deprotection in a dichloromethane solution containing trifluoroacetic acid to obtain a compound 1;
(2) activating carboxyl by using N-hydroxysuccinimide and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, and reacting the activated carboxyl with cyclopeptide cRGD to obtain a compound 2;
(3) deprotecting the compound 2 in N, N-dimethylformamide solution containing piperidine to obtain a compound 3;
(4) and reacting the compound 3 with Cy7 SE to obtain the red light mediated nucleic acid anchoring type fluorescent probe f-CR.
The invention discloses a red light mediated probe cell anchoring method, which comprises the following steps:
(1) carrying out deprotection on tert-butyloxycarbonyl-fluorenylmethyloxycarbonyl-lysine, and then reacting with 3- (2-furan) propionic acid to obtain a compound 1;
(2) activating carboxyl by the compound 1, reacting with cyclopeptide cRGD to obtain a compound 2, and deprotecting to obtain a compound 3;
(3) reacting the compound 3 with Cy7 SE to obtain the red light mediated nucleic acid anchoring type fluorescent probe;
(4) co-incubating the red light mediated nucleic acid anchoring type fluorescent probe, methylene blue and cells to realize the anchoring of the probe to the cells; wherein, the co-incubation is carried out in a culture medium under illumination, and the preferable molar ratio of the red light mediated nucleic acid anchoring type fluorescent probe to the methylene blue is 100: 0.8-1.2, and is preferably 100: 1.
In the technical scheme, tert-butyloxycarbonyl-fluorenylmethyloxycarbonyl-lysine (Boc-Lys (Fmoc) -OH), trifluoroacetic acid and 3- (2-furan) propionic acid react in an organic solvent to obtain a compound 1; carrying out the compound 1, N-hydroxysuccinimide, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and cRGD in an organic solvent to obtain a compound 2; reacting the compound 2 with piperidine in an organic solvent to obtain a compound 3; reacting the compound 3 with Cy7 SE in an organic solvent to obtain an anchored molecular probe f-CR; the molar ratio of the tert-butyloxycarbonyl-fluorenylmethoxycarbonyl-lysine to the 3- (2-furan) propionic acid is 1: 1-1.5; preferably, the molar ratio of the reaction of the t-butyloxycarbonyl-fluorenylmethoxycarbonyl-lysine, the trifluoroacetic acid and the 3- (2-furan) propionic acid is 1: 10: 1.2, the molar ratio of the compound 1 to the N-hydroxysuccinimide, the molar ratio of the 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and the cRGD is 1: 1.2: 1.5: 1.1, the molar ratio of the compound C-1-4 to the piperidine is 1: 10, and the molar ratio of the compound 3 to the Cy7 SE is 1: 1.1.
The invention discloses application of the anchoring molecular probe in preparation of photoacoustic and fluorescent imaging reagents and tumor inhibition.
According to the technical scheme of the invention, the method comprises the following steps:
in the step (1), the reaction of the compound tert-butyloxycarbonyl-fluorenylmethyloxycarbonyl-lysine and trifluoroacetic acid is carried out in dichloromethane, and the molar ratio of the reaction of the tert-butyloxycarbonyl-fluorenylmethyloxycarbonyl-lysine and the trifluoroacetic acid is 1: 10; preferably, the reaction is carried out at room temperature for 0.5 h.
In the step (2), the molar ratio of the compound 1 to the cRGD is 1 to (1-1.2); preferably, compound 1 is reacted with N-hydroxysuccinimide and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride in N, N-dimethylformamide in a molar ratio of 1 to N-hydroxysuccinimide and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride of 1: 1.2: 1.5; preferably, the reaction is at 0oC is reacted for 2 hours at room temperature after 0.5 hour. Then adding cRGD to react in N, N-dimethylformamide solvent containing N, N-diisopropylethylamine, wherein the molar ratio of cRGD to N, N-diisopropylethylamine is 1: 1.1: 1; preferably, the reaction is continued for 2h at room temperature.
In the step (3), the reaction of the compound 2 and piperidine is carried out in N, N-dimethylformamide solvent, and the molar ratio of the compound 2 to piperidine is 1: 10; preferably, the reaction is carried out at room temperature for 0.2 h.
In the step (4), the reaction of the compound 3 with Cy7 SE is carried out in an N, N-dimethylformamide solvent containing N, N-diisopropylethylamine; the molar ratio of the compound 3 to the Cy7 SE is 1 to (1-1.2), and preferably, the molar ratio of the compound 3, the Cy7 SE and the N, N-diisopropylethylamine is 1: 1.1: 1; preferably, the reaction is carried out at room temperature for 1 h.
In the step (5), cRGD reacts with Cy7 SE, and the reaction is carried out in N, N-dimethylformamide solvent containing N, N-diisopropylethylamine; the mol ratio of the compound cRGD, Cy7 SE and N, N-diisopropylethylamine is 1: 1.1: 1; preferably, the reaction is carried out at room temperature for 1 h.
In the present invention, the chemical structural formulas of compound 1, compound 2, compound 3, compound CR, and compound f-CR are as follows:
the compounds CR and f-CR of the present invention are both in the form of internal salts and are shown as conventional in the art.
The invention discloses application of the red light mediated nucleic acid anchoring type fluorescent probe in prolonging imaging time and inhibiting tumor in living body fluorescence imaging or photoacoustic imaging; or the novel anchoring type molecular probe is applied to the preparation of a long-time fluorescence imaging reagent, a photoacoustic imaging reagent or a tumor inhibition reagent; or the novel anchoring molecular probe is cross-linked with RNA in the tumor cell to prolong the application of the fluorescence imaging of the tumor cell; or the novel anchoring type molecular probe is applied to the preparation of tumor cells and the cross-linking with RNA so as to inhibit the growth of the tumor cells.
Due to the application of the technical scheme, compared with the prior art, the invention has the following advantages:
(1) the invention designs and synthesizes a novel anchoring molecular probe f-CR which can perform long-time living body fluorescence and photoacoustic imaging under the condition of generating singlet oxygen by red light mediation;
(2) the target probe can generate cross-linking reaction with RNA in cells under the condition of generating singlet oxygen under the mediation of red light, thereby prolonging the retention time of probe molecules in the cells.
(3) The target probe has good capacity of promoting tumor cell apoptosis after the RNA in the tumor cell is crosslinked.
(4) The target probe has the ability of inhibiting the tumor growth of tumor-bearing mice after the cross-linking reaction in vivo.
Drawings
FIG. 1 is a schematic diagram of the synthesis of the novel anchor-type molecular probe in example 1;
FIG. 2 is a graph showing the chemical structures of (a) the probes f-CR of the experimental group and the probes CR of the control group, (b) the UV absorption and fluorescence emission images of the probes f-CR of the experimental group in an aqueous solution, and (c) the TEM and particle size statistics of the probes f-CR of the experimental group in an aqueous solution in example 2; (d) a particle size distribution map;
FIG. 3 is a gel electrophoresis diagram of (b) RNA and f-CR cross-linking reaction, (c) confocal images and colocalization rate (d) of RNA Select after 6 hours incubation of the experimental group f-CR and the control group probe CR with 4T1 cells respectively, (e) fluorescence and quantification images of total RNA of cells extracted by an RNA population kit, and (f) gel electrophoresis diagram of total cytoplasmic RNA extracted by a nucleus & cytoplasmic RNA extraction kit;
FIG. 4 (a) the retention change and fluorescence intensity quantification of the probe in the cell by confocal picture observation (b) after the probe f-CR in the experimental group and the probe CR in the control group are incubated for 6 hours respectively for the MB and the 4T1 cells, (c) a schematic diagram of the animal experiment, (d) the probe f-CR in the experimental group and the probe CR in the control group are injected into the tumor at first by intratumoral injection and then by caudal vein injection, and the retention change and fluorescence intensity quantification of the probe in the tumor tissue is observed by illumination after one hour (e);
FIG. 5 (a) shows the quantification of photoacoustic signal change and photoacoustic intensity in tumor for the test probe f-CR and the control probe CR under the same test conditions (b), (c) shows the enrichment of the isolated tissue slice in tumor tissue, and (d) shows the quantification of probe in each isolated tissue (heart, liver, spleen, lung, kidney, tumor);
FIG. 6 (a) cytotoxicity Change after incubation of the test group Probe f-CR and the control group Probe CR with MB and 4T1 cells for 12 hours, respectively, (b) illumination (660 nm 50 mW/cm) after incubation of the test group Probe f-CR and the control group Probe CR with MB and 4T1 cells for 12 hours, respectively23 min) post-cytotoxicSex change, (c) the experimental probe f-CR and the control probe CR were incubated with MB and 4T1 cells for 12 h, respectively, and then light irradiation (660 nm, 50 mW/cm)23 min) observing apoptosis changes by live-dead and cell bright fields respectively, (d) transfecting GFP-mRNA into 4T1 cells after in vitro cross-linking reaction with an experimental group probe f-CR and a control group probe CR respectively, observing GFP expression by confocal observation, and observing GFP expression (e) by a flow cytometer, (f) mechanism diagram of cell apoptosis;
FIG. 7 (a) continuous 13-day change curves for tumor inhibition for experimental probe f-CR and control probe CR and blank PBS, respectively, (b) comparative size of tumors in mice on the back on day thirteen, (c) size of isolated tumors on day 13, (d) changes in Tunel, H & E, Caspase 3 were examined 48H post-treatment by immunofluorescence and immunohistochemistry, respectively.
Detailed Description
The invention will be further elucidated with reference to the drawings and specific embodiments. It should be understood that these examples are only for explaining and illustrating the technical solutions of the present invention, and are not intended to limit the scope of the present invention. In addition, unless otherwise specified, materials, reagents, instruments and the like used in the following examples are commercially available; the specific preparation method and the test method are conventional in the field.
The invention constructs and synthesizes the tumor anchoring diagnosis and treatment integration, which comprises the following steps:
the method comprises the following steps of deprotecting tert-butyloxycarbonyl-fluorenylmethoxycarbonyl-lysine in a dichloromethane solution containing trifluoroacetic acid, reacting with 3- (2-furan) propionic acid to obtain a compound 1, activating carboxyl by the compound 1 with N-hydroxysuccinimide and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, reacting with cyclopeptide cRGD to obtain a compound 2, deprotecting in an N, N-dimethylformamide solution containing piperidine to obtain a compound 3, and reacting the compound 3 with Cy7 SE to obtain the anchoring type molecular probe f-CR.
And (3) reacting the cyclic peptide cRGD with Cy7 SE to obtain a probe CR of a control group.
The method for carrying out long-time fluorescence in-vivo imaging by utilizing the novel anchoring molecular probe comprises the following steps of firstly carrying out intratumoral injection on Methylene Blue (MB), then carrying out tail vein injection on the aqueous solution of the novel anchoring molecular probe f-CR and a contrast group CR into the body of a tumor-bearing mouse, and observing in-vivo fluorescence at different time points under an anesthesia state to obtain a photoacoustic imaging effect.
The novel anchored molecular probe f-CR and the water solution of the control group CR are respectively incubated with the tumor cells and the fluorescence intensity in the tumor cells is observed at different time points.
The novel anchoring type molecular probe f-CR and the water solution of the control group CR are respectively incubated with the tumor cells for 48 hours to observe the apoptosis condition of the tumor cells.
The method for carrying out in-vivo tumor inhibition experiment by using the novel anchoring type molecular probe comprises the following steps of firstly carrying out intratumoral injection on methylene blue, then injecting the aqueous solution of the novel anchoring type molecular probe f-CR and the contrast group CR into the body of a tumor-bearing mouse through tail veins, and carrying out continuous observation and recording on the tumor inhibition condition by giving illumination after 1 h.
(1) Novel living body fluorescence imaging of tumor anchoring diagnosis and treatment integrated probe:
after intratumoral injection of MB (concentration: 0.1. mu.M, volume: 50. mu.L) for 0.5 hour, the probe f-CR of the experimental group and the probe CR of the control group obtained above were dissolved in PBS solution (concentration: 100. mu.M, volume: 200. mu.L), respectively, the probes were injected into BALB/c female mice bearing tumors (breast cancer in 4T1 mouse) by tail vein injection, and then placed in an optical imaging system of a mouse living body/IVIS Spectrum (PerkinElmer), and light (660 nm 50 mW/cm) was given to the tumor site after 1 hour 23 min), observing the imaging effect in real time, and finally calculating the fluorescence intensity of the tumor part of the mouse at different time points by using living body imaging analysis software.
(2) Novel living body photoacoustic imaging of tumor anchoring type diagnosis and treatment integrated probe:
after intratumoral injection of MB (concentration: 0.1. mu.M, volume: 50. mu.L) for 0.5 hour, the experimental probe f-CR and the control probe CR obtained above were dissolved in PBS solution (concentration: 100. mu.L), respectivelyM, volume: 200 mu L) and injecting the probe into a BALB/c female mouse with tumor (breast cancer of a 4T1 mouse) by tail vein injection, simultaneously opening a photoacoustic tomography imaging system of the mouse, placing the mouse after anesthesia when the water temperature in a water bath of a photoacoustic imager reaches 37 ℃, and scanning the tumor part image of the mouse. And 1 hour later, the tumor site was irradiated with light (660 nm, 50 mW/cm)2And 3 min), observing the imaging effect in real time, and finally calculating the fluorescence intensity of the tumor part of the mouse at different time points by using living body imaging analysis software. The obtained photoacoustic imaging data was then subjected to reconstruction analysis using MSOT InSight/inVision analysis software.
(3) Novel tumor inhibition experiment of tumor anchoring diagnosis and treatment integrated probe:
BALB/c female mice bearing bilateral dorsal tumors (breast cancer in 4T1 mice) with tumor volumes of about 20 mm3) Randomly divided into 3 groups (n ═ 5): left tumors (group 1, PBS for short) of mice injected with PBS (10 mM, 200. mu.L) in tail vein, 660 nm laser-irradiated right tumors (group 2, PBS for short +660 nm); tail vein-only CR (200. mu.M, 200. mu.L) and pre-intratumoral injection of MB (concentration: 0.1. mu.M, volume: 50. mu.L) left tumor (group 3, abbreviated CR + MB), right tumor pre-intratumorally injected MB (concentration: 0.1. mu.M, volume: 50. mu.L) and 660 nm laser-irradiated treated mice (group 4, abbreviated CR + MB +660 nm); tail vein injection of f-CR (200. mu.M, 200. mu.L) and preliminary intratumoral injection of MB (concentration: 0.1. mu.M, volume: 50. mu.L) left tumors (group 3, abbreviated as f-CR + MB), right tumors were preliminary intratumoral injection of MB (concentration: 0.1. mu.M, volume: 50. mu.L) and 660 nm laser-irradiated treated mice (group 4, abbreviated as f-CR + MB +660 nm). After treatment, mice tumor volume changes were recorded every other day and mice survival curves were plotted.
Example 1: synthesis of novel tumor anchoring diagnosis and treatment integrated probe CR and f-CR
Synthesis of compound 1: Boc-Lys (Fmoc) -OH (0.5 g, 1.07 mmol) was dissolved in dichloromethane 10 mL while adding trifluoroacetic acid 2 mL and stirring at room temperature for 10 min to remove BOC, followed by collection of product and addition of 3- (2-furan)) Propionic acid (0.2 g, 1.43 mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.82 g, 1.43 mmol) and N-hydroxysuccinimide (0.2 g, 1.71 mmol) were stirred at room temperature for 4 h and N, N-diisopropylethylamine (5. mu.L) was added and the reaction was continued for 3 h. After the reaction was completed, it was extracted three times with ethyl acetate and then concentrated, followed by elution through a silica gel column to obtain pure product compound 1 (0.56 g, 80%). C28H30N2O6 ([M+H]+): 489.2021, found ESI-MS: m/z 489.2031；
Synthesis of Compound 2: cRGD (10 mg, 16.57. mu. mol) and 1 (19.47 mg, 33.13. mu. mol) were dissolved in DMF (5 mL) and stirred at 0 ℃ for 10 min followed by the slow addition of DIPEA (2. mu.L) simultaneously. After reacting for two hours at room temperature, collecting the product, and separating the product by using preparative HPLC to obtain a product compound 2C55H69N11O12 ([M-H]-): 1076.5190, found ESI-MS: m/z 1076.5187；
Synthesis of Compound 3: compound 2 (10 mg, 9.29. mu. mol) was dissolved in DMF/diethylamine (6 mL, 5:1, v/v) solution and reacted for 1 h at room temperature. The crude product was concentrated and the product was isolated by preparative HPLC to afford the product compound 3. C40H59N11O10 ([M-H]-): 852.4374, found ESI-MS: m/z 852.4370；
Synthesis of Compound f-CR: compound 3 (5 mg, 5.86. mu. mol), Cy7-SE (4.24 mg, 5.86. mu. mol) was dissolved in DMF (2 mL) and stirred at 0 ℃ for 10 min while dropwise adding to the reaction system, and after allowing to react for 2h at room temperature, a sample was separated by preparative HPLC to give the final product. C75H99N13O17S2 ([M-H]-): 1516.6651, found ESI-MS: m/z 1516.6664。
Synthesis of cRGD (5 mg, 8.27. mu. mol) as control Compound CR, Cy7-SE (5.99 mg, 8.27. mu. mol) was dissolved in DMF (2 mL) and DIPEA was added slowly and stirred at 0 ℃ for 10 min and then at room temperature for 2h with continued stirring to collect the crude product which was isolated by preparative HPLC to give a control product. C62H81N11O14S2 ([M-H]-): 1266.5339, found ESI-MS: m/z 1266.5321。
The reaction scheme and the chemical structural formula related to each part product are shown in figure 1.
Example 2: physicochemical properties of novel tumor anchoring diagnosis and treatment integrated probe
The control probe CR and the test probes f-CR prepared in example 1 were diluted with ultrapure water to a concentration of 10. mu.M (which was completely dissolved), and the ultraviolet-visible near-infrared spectrum and the fluorescence spectrum thereof were measured using an ultraviolet-visible near-infrared spectrophotometer and a fluorescence spectrophotometer. As shown in FIG. 2 (a) (b), the results show that the maximum absorption of probes CR and f-CR is 747 nm and the maximum emission is 789 nm; meanwhile, the control group of probes have no assembly and no nano structure, while the experimental group of probes have the assembly and the nano structure, and the size of the nano structure is larger than 7.2 +/-0.9 nm, as shown in (c) (d) of FIG. 2.
The control probe CR and the test probe f-CR prepared in example 1 were diluted with ultrapure water to a concentration of 10. mu.M, 5. mu.M custom sequence RNA (5 '-ACAUCGGGAUAGCGAAGUUGAGAGAGAGGGAG-3') was added, 10. mu.M MB was mixed, and the mixture was shaken at 4 ℃ and irradiated with light (50 mW/cm) at 660 nm 210 minutes) or not (keeping out of the light), the reaction solution is directly separated by RNA non-denaturing gel electrophoresis, as shown in FIG. 3b, the experimental group probe f-CR can be obviously labeled with RNA after adding RNA and MB and giving light, and the other groups have no obvious red fluorescence of Cy 7. The control probe CR and the test probe f-CR were added to a culture medium (Hyclone DMEM high-sugar liquid medium containing 10% FBS) at a concentration of 10. mu.M, 0.1. mu.M of MB was added thereto, and the mixture was cultured in 4T1 cells for 6 hours, followed by giving illumination at 660 nm (50 mW/cm)210 min) or not (dark), then using commercial RNA dye SYTO ™ RNaselect-green fluorescent cell stain (Thermo Fisher) to stain respectively as shown in FIG. 3d, and finding that the co-localization rate in the experimental group (f-CR + MB +660 nm) is higher than that in other groups in the co-localization experiment of the probe; then extracting total RNA in the cells by a Trizol method, and finding that the fluorescence intensity of an experimental group (f-CR + MB +660 nm) is far higher than that of other groups by fluorescence quantification as shown in figure 3 e; then through the cytoplasm&Extracting cytoplasm RNA from the total nucleus extraction kit and separating the cytoplasm RNA by using an RNA non-denaturing gelThe analysis found that the experimental group (f-CR + MB +660 nm) had significant red fluorescence, and the other groups had no significant fluorescence as shown in FIG. 3 f.
Control Probe CR and Experimental Probe f-CR were added to a medium (Hyclone DMEM high-sugar liquid medium containing 10% FBS) at a concentration of 10. mu.M, MB was added at 0.1. mu.M, and the mixture was cultured in 4T1 cells for 6 hours, followed by giving illumination at 660 nm (50 mW/cm)210 minutes) or not (protected from light), the retention of the material in the cells was observed, and the retention experiment in the experimental group (f-CR + MB +660 nm) was found to be much larger than that in the other groups such as FIGS. 4a and 4 b; then, in the experiment of examining the retention of the probe in the tumor of the mouse, the control probe CR and the test probe f-CR were injected into the tumor of the mouse with PBS at a concentration of 100 μ M200. mu.L at 0.5h in advance of the MB (PBS, 0.1. mu.M 50. mu.L) intratumorally, followed by administration of the tail vein injection CR or f-CR, and 1 h later with 660 nm light (50 mW/cm)23 min) or not (protected from light), the intra-tumor metabolism of the probe at each time point was observed by IVIS as shown in FIGS. 4c, 4d and 4e, and the retention time of the experimental group (f-CR + MB +660 nm) in vivo was found to be much longer than that of the other groups.
Control group Probe CR and Experimental group Probe f-CR were intratumorally injected into mouse tumors with PBS to a concentration of 100 μ M200 μ L0.5 h in advance, followed by caudal vein injection of CR or f-CR, and 660 nm illumination (50 mW/cm) 1 h later, using PBS to give an intratumoral injection of MB (PBS, 0.1 μ M50 μ L) into the mice tumors 23 minutes) or not (shielded from light), and simultaneously observing the change condition of the photoacoustic signal at each time point through a photoacoustic imaging system, performing reconstruction analysis on the photoacoustic imaging data by using MSOT InSight/INVision analysis software, and finding that an experimental group (f-CR + MB +660 nm) has a long-time photoacoustic signal compared with other groups, as shown in FIGS. 5a and 5 b; in the same experimental method as the above, after the probe is injected for 12 h, each main organ of the mouse is taken out, the tumor tissue is frozen and sliced, the graph is shown in 5c, the quantitative fluorescence intensity of the homogenate of all organ tissues is shown in 5d, and the enrichment amount of the experimental group (f-CR + MB +660 nm) in the tumor is far greater than that of other groups.
Control group Probe CR and Experimental group Probe f-CR Medium (Hyclone DMEM high sugar liquid Medium containing 10% FB)S) was diluted to a concentration of 100, 50, 20, 10, 1, 0.1. mu.M of MB was added, and after 12 h of culture in 4T1 cells, neither CR nor f-CR was found to have significant toxicity as shown in FIG. 6a, under the same experimental conditions at 660 nm (50 mW/cm) light exposure 23 min) for another 48 h, the experimental group (f-CR + MB +660 nm) was found to exhibit some cytotoxicity as shown in FIG. 6 b; meanwhile, the experimental group (f-CR + MB +660 nm) shows the capability of causing tumor cell apoptosis through the Live-dead reagent and the morphology of the cell bright field.
Using commercial GFP-mRNA 2. mu.M, control probe CR and experimental probe f-CR, the samples were diluted with PBS to a concentration of 10. mu.M, and MB was added at 0.1. mu.M, and the samples were subjected to conventional shaking at 4 ℃ while giving illumination at 660 nm (50 mW/cm)23 minutes) or not (protected from light), then each mixed solution is transfected into cells by a lipofection kit to be cultured for 24 hours, an experimental group (f-CR + MB +660 nm) shows a remarkable reduction of the expression of the GFP in the cells under a confocal picture, and an experimental group (f-CR + MB +660 nm) shows a reduction of the expression amount of the GFP by analyzing the cells through a flow cytometer is collected and is shown as figure 6 e.
Tumor suppression experiments, control Probe CR and Experimental Probe f-CR were performed using PBS to a concentration of 200 μ M to 200 μ L, and MB (PBS, 0.1 μ M to 50 μ L) was injected intratumorally into mice tumors 0.5h in advance, followed by caudal vein injection of CR or f-CR, and 660 nm light (50 mW/cm) 1 h later23 min) or not (protected from light), then the tumor size was taken daily as in fig. 7a, the mice were sacrificed on day thirteen as in fig. 7b, and the tumors were taken off as in fig. 7c, and it was found that the experimental group (f-CR + MB +660 nm) had good tumor suppression ability, and the mice tumors were taken on day one under the same conditions, and subjected to H&E, immunohistochemistry and immunofluorescence analysis of Tunnel and Caspase-3 result that the probes of the experimental group (f-CR + MB +660 nm) can cause the tumor tissues to generate apoptosis and necrosis.
The anchoring type molecular probe provided by the invention is used for improving the retention time of molecules in tumor tissues and inhibiting the growth of tumors by utilizing red light mediated biological crosslinking. The intra-tumor metabolism of the probe at each time point was observed by IVIS, and the retention time of the experimental group (f-CR + MB +660 nm) in vivo was found to be much longer than that of the other groups.
Claims (10)
1. A red light-mediated nucleic acid anchoring type fluorescent probe is characterized by having the following chemical structural formula:
2. the use of the red light-mediated nucleic acid-anchored fluorescent probe of claim 1 for in vivo fluorescence, photoacoustic imaging, and tumor suppression; or the application of the red light mediated nucleic acid anchoring type fluorescent probe in the preparation of living body fluorescence, photoacoustic imaging reagents and tumor inhibition reagents according to claim 1; or the use of the red light mediated nucleic acid anchored fluorescent probe of claim 1 for increasing the retention time of the probe in tumor tissue and inhibiting tumors.
3. The method for preparing a red light-mediated nucleic acid-anchored fluorescent probe according to claim 1, comprising the steps of:
(1) carrying out deprotection on tert-butyloxycarbonyl-fluorenylmethyloxycarbonyl-lysine, and then reacting with 3- (2-furan) propionic acid to obtain a compound 1;
(2) activating carboxyl by the compound 1, reacting with cyclopeptide cRGD to obtain a compound 2, and deprotecting to obtain a compound 3;
(3) and reacting the compound 3 with Cy7 SE to obtain the red light mediated nucleic acid anchoring type fluorescent probe.
4. The method for preparing the red-light mediated nucleic acid anchored fluorescent probe according to claim 3, wherein t-butyloxycarbonyl-fluorenylmethyloxycarbonyl-lysine is deprotected in a dichloromethane solution containing trifluoroacetic acid; compound 1 activates the carboxyl group with N-hydroxysuccinimide and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride.
5. The method for preparing the red light-mediated nucleic acid-anchored fluorescent probe according to claim 3, wherein in the step (1), the molar ratio of tert-butyloxycarbonyl-fluorenylmethoxycarbonyl-lysine to 3- (2-furan) propionic acid is 1: 1-1.5; the reaction was carried out at room temperature.
6. The method for preparing a red-light-mediated nucleic acid-anchored fluorescent probe according to claim 3, wherein in the step (2), the molar ratio of the compound 1 to the cRGD is 1 to (1-1.2); the reaction was carried out at room temperature.
7. The method for preparing a nucleic acid-anchored fluorescent probe mediated by red light according to claim 3, wherein in the step (3), the reaction of compound 3 with Cy7 SE is carried out in a solvent containing N, N-diisopropylethylamine; the molar ratio of the compound 3 to the Cy7 SE is 1: 1-1.2.
8. A method of red light mediated probe anchoring a cell comprising the steps of:
(1) carrying out deprotection on tert-butyloxycarbonyl-fluorenylmethyloxycarbonyl-lysine, and then reacting with 3- (2-furan) propionic acid to obtain a compound 1;
(2) activating carboxyl by the compound 1, reacting with cyclopeptide cRGD to obtain a compound 2, and deprotecting to obtain a compound 3;
(3) reacting the compound 3 with Cy7 SE to obtain the red light mediated nucleic acid anchoring type fluorescent probe;
(4) and co-incubating the red light mediated nucleic acid anchoring type fluorescent probe, methylene blue and cells to realize the anchoring of the probe to the cells.
9. The red-light mediated probe-anchored cell method of claim 8, wherein the co-incubation is performed in culture medium under light.
10. The method for anchoring cells by using the red light-mediated probe, according to claim 8, wherein the molar ratio of the red light-mediated nucleic acid anchoring type fluorescent probe to the methylene blue is 100 to (0.8-1.2).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011263517.1A CN112592386B (en) | 2020-11-12 | 2020-11-12 | Red light mediated nucleic acid anchoring type fluorescent probe and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011263517.1A CN112592386B (en) | 2020-11-12 | 2020-11-12 | Red light mediated nucleic acid anchoring type fluorescent probe and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112592386A true CN112592386A (en) | 2021-04-02 |
| CN112592386B CN112592386B (en) | 2022-04-15 |
Family
ID=75182853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011263517.1A Active CN112592386B (en) | 2020-11-12 | 2020-11-12 | Red light mediated nucleic acid anchoring type fluorescent probe and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112592386B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024060196A1 (en) * | 2022-09-23 | 2024-03-28 | 苏州大学 | Rna reaction type fluorescent probe, preparation method therefor, and use thereof |
| WO2024152405A1 (en) * | 2023-01-18 | 2024-07-25 | 苏州大学 | Diagnosis and treatment integrated nucleic acid anchoring-type fluorescent probe and preparation method therefor and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108055852A (en) * | 2015-07-16 | 2018-05-18 | 香港科技大学 | Emit red or yellow fluorescent aggregation inducing emitting biological probe |
| CN110684017A (en) * | 2019-09-20 | 2020-01-14 | 苏州大学 | High-stability near-infrared two-region small-molecule fluorescent probe and preparation method and application thereof |
| US20200131370A1 (en) * | 2018-10-24 | 2020-04-30 | California Institute Of Technology | Near-Infrared Heptamethine Dyes For Generation Of Singlet Oxygen |
-
2020
- 2020-11-12 CN CN202011263517.1A patent/CN112592386B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108055852A (en) * | 2015-07-16 | 2018-05-18 | 香港科技大学 | Emit red or yellow fluorescent aggregation inducing emitting biological probe |
| US20200131370A1 (en) * | 2018-10-24 | 2020-04-30 | California Institute Of Technology | Near-Infrared Heptamethine Dyes For Generation Of Singlet Oxygen |
| CN110684017A (en) * | 2019-09-20 | 2020-01-14 | 苏州大学 | High-stability near-infrared two-region small-molecule fluorescent probe and preparation method and application thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024060196A1 (en) * | 2022-09-23 | 2024-03-28 | 苏州大学 | Rna reaction type fluorescent probe, preparation method therefor, and use thereof |
| WO2024152405A1 (en) * | 2023-01-18 | 2024-07-25 | 苏州大学 | Diagnosis and treatment integrated nucleic acid anchoring-type fluorescent probe and preparation method therefor and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112592386B (en) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109180680B (en) | Ultraviolet light triggered crosslinking near-infrared molecular probe and preparation method and application thereof | |
| CN112592386B (en) | Red light mediated nucleic acid anchoring type fluorescent probe and preparation method and application thereof | |
| CN109678966B (en) | Brain tumor targeting peptide and application thereof | |
| CN114149482B (en) | Intelligent conversion dual-stimulus response type probe for chelating metal ions and preparation method and application thereof | |
| CN111097052B (en) | Amphiphilic prodrug for active targeted therapy of tumors and preparation method and application of nanoparticles of amphiphilic prodrug | |
| CN113144171B (en) | Polypeptide nano-drug with oxidation response morphology transformation | |
| CN112794917B (en) | Polypeptide imaging probe and preparation method and application thereof | |
| CN112442117B (en) | Tumor imaging and treating probe targeting follicle-stimulating hormone receptor, and preparation method and application thereof | |
| CN116217515B (en) | Methylene blue probe, preparation method thereof and application thereof in detection of cysteine | |
| CN106512029A (en) | Nano-probe with apoptosis target function and preparation and application | |
| WO2023245857A1 (en) | Capsaicin-derived photosensitizer, and preparation method therefor and use thereof | |
| CN116554274A (en) | Preparation method and application of near infrared fluorescent probe for tumor targeted imaging | |
| US20230407169A1 (en) | Red-light-mediated nucleic acid anchoring-type fluorescent probe, and preparation method therefor and use thereof | |
| Men et al. | ανβ3 integrin-targeted ICG-derived probes for imaging-guided surgery and photothermal therapy of oral cancer | |
| CN113912607A (en) | SNAP-tag probe and preparation method and application thereof | |
| CN113388003A (en) | Aspartic acid proteolytic enzyme recognition reduction type molecular probe and application | |
| WO2024152405A1 (en) | Diagnosis and treatment integrated nucleic acid anchoring-type fluorescent probe and preparation method therefor and use thereof | |
| CN114949248B (en) | Targeted synergistic retention type nanoparticle as well as preparation method and application thereof | |
| CN113980013B (en) | Compound based on cyanine dye and preparation method and application thereof | |
| CN118048050B (en) | Heptamethine cyanine near-infrared fluorescent dye and preparation method and application thereof | |
| CN111603573B (en) | SPECT molecular image probe and preparation method and application thereof | |
| WO2020024302A1 (en) | Ultraviolet light triggered crosslinking near-infrared molecular probe and preparation method and application therefor | |
| CN115678545B (en) | Near infrared two-region luminous gold nano material synthesized based on CB [7] and application thereof | |
| CN114835723B (en) | PSMA fluorescent molecular probe, preparation method and kit | |
| CN117164672A (en) | Near infrared two-region fluorescent probe for targeting melanoma, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |